Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer

Journal of Clinical Oncology

Volumn 34, Issue 8, 2016, Pages 825-832

  Galsky, Matthew D ^a   Stensland, Kristian D ^b   Moshier, Erin ^a   Sfakianos, John P ^a   McBride, Russell B ^a   Tsao, Che Kai ^a   Casey, Martin ^a   Boffetta, Paolo ^a   Oh, William K ^a   Mazumdar, Madhu ^a   Wisnivesky, Juan P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYSTECTOMY; DRUG EFFICACY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPENSITY SCORE; ADJUVANT CHEMOTHERAPY; CARCINOMA, TRANSITIONAL CELL; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84961140758     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.1076     Document Type: Article

References (36)

1. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
2. Galsky MD, Herr HW, Bajorin DE: The integration of chemotherapy and surgery for bladder cancer. J Natl Compr Canc Netw 3:45-51, 2005
3. Griffiths G, Hall R, Sylvester R, et al: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol 29:2171-2177, 2011 10.1200/JCO.2010.32.3139.
4. Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and metaanalysis. Lancet 361:1927-1934, 2003
5. Advanced Bladder Cancer (ABC) Metaanalysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202-205, 2005; discussion 205-206
6. David KA, Milowsky MI, Ritchey J, et al: Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base. J Urol 178:451-454, 2007
7. Booth CM, Siemens DR, Peng Y, et al: Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice. Ann Oncol 25:1783-1788, 2014
8. Reardon ZD, Patel SG, Zaid HB, et al: Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: A sign of changing tides. Eur Urol 67:165-170, 2015
9. Freiha F, Reese J, Torti FM: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155:495-499, 1996; discussion 499-500
10. Studer UE, Bacchi M, Biedermann C, et al: Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: Results of a prospective randomized trial. J Urol 152:81-84, 1994
11. Stöckle M, Meyenburg W, Wellek S, et al: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy-Results of a controlled prospective study. J Urol 148:302-306, 1992; discussion 306-307
12. Skinner DG, Daniels JR, Russell CA, et al: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 145:459-464, 1991; discussion 464-467
13. Paz-Ares LG, Solsona E, Esteban E, et al: Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 28:346s, 2010 (suppl; abstr LBA4518)
14. Cognetti F, Ruggeri EM, Felici A, et al: Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: An Italian, multicenter, randomized phase III trial. Ann Oncol 23:695-700, 2012
15. Sternberg CN, Skoneczna I, Kerst JM, et al: European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology: Immediate versus deferred chemotherapy after radical cystectomyinpatients withpT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): An intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16:76-86, 2015
16. National Comprehensive Cancer Network: Bladder cancer guideline (version 2.2014). http://www.nccn.org/professionals/physician-gls/pdf/bladder.pdf
17. Witjes JA, Compérat E, Cowan NC, et al: EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol 65:778-792, 2014
18. Steele GD Jr, Winchester DP, Menck HR: The National Cancer Data Base: A mechanism for assessment of patient care. Cancer 73:499-504, 1994
19. Stuart EA, Azur M, Frangakis C, et al: Multiple imputation with large data sets: A case study of the Children's Mental Health Initiative. Am J Epidemiol 169:1133-1139, 2009
20. Austin PC: Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: A systematic review and suggestions for improvement. J Thorac Cardiovasc Surg 134:1128-1135, 2007
21. Ming K, Rosenbaum PR: Substantial gains in bias reduction from matching with a variable number of controls. Biometrics 56:118-124, 2000
22. Faries D, Leon A, Haro J, et al (eds): Analysis of Observational Health Care Data Using SAS. Cary, NC, SAS Institute, 2010
23. Austin PC: Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf 17:1218-1225, 2008
24. Lin DY, Psaty BM, Kronmal RA: Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 54:948-963, 1998
25. Eisenberg MS, Boorjian SA, Cheville JC, et al: The SPARC score: A multifactorial outcome prediction model for patients undergoing radical cystectomy for bladder cancer. J Urol 190:2005-2010, 2013
26. Boorjian SA, Kim SP, Tollefson MK, et al: Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol 190:55-60, 2013
27. Stensland KD, McBride RB, Latif A, et al: Adult cancer clinical trials that fail to complete: An epidemic? J Natl Cancer Inst 106: dju229, 2014
28. Booth CM, Tannock IF: Randomised controlled trials and population-based observational research: Partners in the evolution of medical evidence. Br J Cancer 110:551-555, 2014
29. Advanced Bladder Cancer (ABC) Metaanalysis Collaboration: Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data-Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 48:189-201, 2005
30. Leow JJ, Martin-Doyle W, Fay AP, et al: A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529-541, 2014
31. Froehner M, Koch R, Heberling U, et al: Decreased overall and bladder cancer-specific mortality with adjuvant chemotherapy after radical cystectomy: Multivariable competing risk analysis. Eur Urol [epub ahead of print on July 17, 2015]
32. Kim HS, Piao S, Moon KC, et al: Adjuvant chemotherapy correlates with improved survival after radical cystectomy in patients with pT3b (macroscopic perivesical tissue invasion) bladder cancer. J Cancer 6:750-758, 2015
33. Svatek RS, Shariat SF, Lasky RE, et al: The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16:4461-4467, 2010
34. Booth CM, Siemens DR, Li G, et al: Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer 120:1630-1638, 2014
35. Culleton BF, Larson MG, Wilson PW, et al: Cardiovascular disease and mortality in a communitybased cohort with mild renal insufficiency. Kidney Int 56:2214-2219, 1999
36. Garg AX, Clark WF, Haynes RB, et al: Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 61:1486-1494, 2002